Denmark's Novo Nordisk, the world's top insulin maker, said Friday it has acquired a British firm that is pioneering a new technology which could help people with diabetes inject themselves more safely with insulin. Novo Nordisk said in a statement it has acquired Bristol-based Ziylo in a deal that could potentially exceed $800 million.
Ziylo describes itself as a scientific incubator that is developing glucose responsive insulins or GRIs. A GRI would "help eliminate the risk of hypoglycaemia, the main risk associated with insulin therapy and one of the main barriers to achieving optimal glucose control," Novo Nordisk said in a statement. Hyperglycemia or high blood sugar is when there is an excessive amount of glucose in a person's blood. And insulins are used to lower those levels.
Comments
Comments are closed.